# Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas

> **NCT02343406** · PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 266 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Depatuxizumab mafodotin
- **DRUG:** Temozolomide
- **DRUG:** Lomustine

## Key facts

- **NCT ID:** NCT02343406
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-17
- **Primary completion:** 2019-06-24
- **Final completion:** 2019-06-24
- **Target enrollment:** 266 (ACTUAL)
- **Last updated:** 2020-05-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02343406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02343406, "Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02343406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*